14 Sep, 2025
2 mins read

Iza-bren and osimertinib combination shows 100% response rate in EGFR-mutated lung cancer

[ad_1] Credit: Unsplash/CC0 Public Domain A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This study was presented at the International Association for the Study of Lung Cancer 2025 World […]

2 mins read

Osimertinib plus chemotherapy improves progression-free survival in EGFR-mutated non-small cell lung cancer

[ad_1] Credit: Pixabay/CC0 Public Domain A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study was presented at the International Association for the Study […]

3 mins read

Satellites confirm 1990s sea-level predictions were shockingly accurate

[ad_1] Global sea-level change has now been measured by satellites for more than 30 years, and a comparison with climate projections from the mid-1990s shows that they were remarkably accurate, according to two Tulane University researchers whose findings were published in Earth’s Future, an open-access journal published by the American Geophysical Union. “The ultimate test […]

2 mins read

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

[ad_1] Credit: CC0 Public Domain A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Iza-bren is a first-in-class […]